A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia

Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekiguchi, Naohiro, Rai, Shinya, Munakata, Wataru, Suzuki, Kenshi, Handa, Hiroshi, Shibayama, Hirohiko, Endo, Tomoyuki, Terui, Yasuhito, Iwaki, Noriko, Fukuhara, Noriko, Tatetsu, Hiro, Iida, Shinsuke, Ishikawa, Takayuki, Shiibashi, Ryota, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469793/
https://www.ncbi.nlm.nih.gov/pubmed/32639651
http://dx.doi.org/10.1111/cas.14561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469793/
https://www.ncbi.nlm.nih.gov/pubmed/32639651
http://dx.doi.org/10.1111/cas.14561

Ejemplares similares